Compositions for the Treatment of Cancer, and Methods for Testing and Using the Same
AssigneeRutgers, The State University of New Jersey
InventorScott Kachlany
Life of this patent
Estimating the term…
Abstract
The invention relates to pharmaceutical compositions comprising leukotoxin, including methods to treat lymphoma, and methods to diagnose lymphoma. The lymphoma includes lymphoma cells expressing activated LFA-1, and the leukotoxin binds to the activated LFA-1 on the lymphoma cells and destroys the lymphoma cells by apoptosis or necrosis, thereby treating said lymphoma.
Claims17
A method for treating lymphoma in a subject in need thereof comprising administering a composition comprising a therapeutically effective amount of leukotoxin protein to the subject, wherein said lymphoma comprises lymphoma cells expressing activated LFA-1, and wherein said leukotoxin binds to said activated LFA-1 on said lymphoma cells and destroys said lymphoma cells by apoptosis or necrosis, thereby treating said lymphoma, and wherein the leukotoxin protein comprises the sequence of SEQ ID NO:
- 1.
(canceled)
(canceled)
A method for determining whether a subject has lymphoma, comprising
- a. obtaining from the subject a sample that contains white blood cells;
- b. contacting the sample with leukotoxin;
- and
- c. determining the percentage of the white blood cells that bind to the leukotoxin in the sample;
- wherein the subject is determined to have the disorder if the percentage is at or above a predetermined value.
A method for determining the effectiveness of a treatment in a patient suffering from lymphoma, comprising
- a. obtaining a sample that contains white blood cells from a patient that has received a treatment;
- b. contacting the sample with leukotoxin;
- and
- c. determining the percentage of the white blood cells that bind to the leukotoxin in the sample;
- wherein the treatment is determined to be effective if the percentage is below a predetermined value.
A method to reduce lymphoma tumor cells in a subject, the method comprising
- a. identifying a subject having lymphoma, and
- b. reducing the level of cells expressing activated LFA-1 in the subject using an anti-LFA-1 agent,
- wherein the anti-LFA-1 agent is a leukotoxin or a chemotherapeutic agent.
A pharmaceutical composition, comprising, an anti-LFA-1 agent that specifically binds to and causes death of cells expressing activated LFA-1, wherein said anti-LFA-1 agent is a leukotoxin or an anti-cancer chemotherapeutic agent, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.